Noom expands its GLP-1 range with 'microdose' package Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price
Perfectly measurable
Tyna: I have a four-part video series where I dive into this in a bit more detail
Trading companies do not manufacture peptides
Athletes can still use substances in the Monitoring Program, but WADA has decided to track these items in order to detect potential patterns of misuse in sport, Fitzgerald says, and identify whether any of them could enhance performance or pose a health risk
The study authors are independent from the funders, they had full access to all the data (including statistical reports and tables), they are responsible for the integrity of the data and the accuracy of the data analysis, and they accept responsibility to submit for publication